Effects of Nutritional Supplement with α-Lipoic Acid in Patients with Recurrent Pterygium
|Jorge Guillermo Hurtado Godinez1, Leonel Garcia Benavides1*, Sara Pascoe Gonzalez1, Ivan Isidro Hernandez Cañaveral1, Francisco Javier Galvez Gastelum1 and Irinea Yañez Sanchez2|
|1 INTEC, Departamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Jalisco, México|
|2 Centro de Investigación en Nanociencia y Nanotecnología, Centro Universitario de los Valles, Universidad de Guadalajara, Jalisco, México|
|Corresponding Author :||Leonel García Benavides M.D., PhD
Instituto de Terapéutica Experimentaly Clínica Departamento de Fisiología
CUCS, U de G, Sierra Mojada 950, edificio P
1° piso, Colonia Independencia, CP 44340
Guadalajara, Jalisco, México
Tel: (52)(33)10585200 ext. 33659, 33660
Email: [email protected]
|Received: February 13, 2014; Accepted: May 13, 2014; Published: May 20, 2014|
|Citation: Godinez JGH, Benavides LG, Gonzalez SP, Cañaveral IIH, Gastelum FJG, et al. (2014) Effects of Nutritional Supplement with a-Lipoic Acid in Patients with Recurrent Pterygium. J Clin Exp Ophthalmol 5:338. doi:10.4172/2155-9570.1000338|
|Copyright: © 2014 Godinez JGH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.|
|Related article at
Pubmed Scholar Google
Background: Pterygium is an ocular disease characterized by fibro-proliferative disarray of the corneal surface. Control of oxidative stress with effective antioxidant supplementation, like α-lipoic acid, could prevent recurrence following surgical resection.
Materials and methods: This study was a randomized placebo-controlled, double-blind trial. Seventy patients with recurrent pterygium participated. Oral therapy with α-lipoic acid or placebo was administered. Pterygium tissue was collected for histological and immunohistochemical analysis.
Results: Pterygium recurrence was similar in both groups. A significant increment of fibroelastic tissue was observed in the placebo compared with the α-lipoic acid group. Number and caliber of blood vessels, extracellular matrix content and presence of inflammatory infiltrated cells decreased in the α-lipoic acid group. Myofibroblasts were also localized and smaller.
Conclusions: Treatment with α-lipoic acid improved clinical appearances through decreased fibroelastic tissue size. Recurrence was similar. Blood vessels, extracellular matrix content and inflammatory infiltrated cells reduced with α-lipoic acid.